Recombinant gp 120 Subunit Vaccines Virus Type 1 while Participating in Trials of Persons Infected by Human Immunodeficiency Immunological and Virological Analyses of

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• CD4, CXCR-4, and CCR-5 dependencies for infections by primary patient and laboratory-adapted isolates of human immunodeficiency virus type 1

  1997influential reference
• Physico-chemical Analyses of the Humoral Immune Response to HIV-1 : Quantification of Antibodies , Their Binding to Viral Antigens and Neutralization of Viral Infectivity

  1997cited by this paper
• Longitudinal Analysis of Quantitative Virologic Measures in Human Immunodeficiency Virus-Infected Subjects with ⩾400 CD4 Lymphocytes: Implications for Applying Measurements to Individual Patients

  1997cited by this paper
• Mucosal immune responses in four distinct compartments of women infected with human immunodeficiency virus type 1: a comparison by site and correlation with clinical information.

  1997cited by this paper
• Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex

  1997cited by this paper
• Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1

  1997cited by this paper
• Drift from the GPGRAF HIV-1 Envelope V3 Crown Sequence in a North American Inner City

  1997cited by this paper
• Change in Coreceptor Use Correlates with Disease Progression in HIV-1–Infected Individuals

  1997influential reference
• Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: performance criteria for selecting candidate antibodies for clinical trials. AIDS Clinical Trials Group Antibody Selection Working Group.

  1997cited by this paper
• Viral load in asymptomatic patients with CD4+ lymphocyte counts above 500 × 106/l

  1997cited by this paper
• Adaptive Evolution of Human Immunodeficiency Virus-Type 1 During the Natural Course of Infection

  1996cited by this paper
• The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate

  1996cited by this paper
• Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma

  1996influential reference
• Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. The WHO Network for HIV Isolation and Characterization

  1996cited by this paper
• Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry

  1996cited by this paper
• Titration of a Vaccine Stock Preparation of Human Immunodeficiency Virus Type 1sf2 in Cultured Lymphocytes and in Chimpanzees

  1996cited by this paper
• Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study.

  1996influential reference
• HIV viral load markers in clinical practice

  1996cited by this paper
• Human immunodeficiency virus type 1 infection despite prior immunization with a recombinant envelope vaccine regimen.

  1996cited by this paper
• Antigenic determinants on HIV‐1 envelope glycoproteins: a Dickens of a time with Oligomer Twist

  1996cited by this paper
• Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein

  1996cited by this paper
• Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes

  1996cited by this paper
• Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.

  1996cited by this paper
• Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1.

  1996cited by this paper
• Multivariate analysis of human immunodeficiency virus type 1 neutralization data

  1996cited by this paper
• Variations in immunoglobulins and IgA subclasses of human uterine cervical secretions around the time of ovulation

  1996cited by this paper
• Human Immunodeficiency Virus Type 1 Neutralizing Antibody Serotyping Using Serum Pools and an Infectivity Reduction Assay

  1996cited by this paper
• Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene

  1996cited by this paper
• The role of a mutant CCR5 allele in HIV–1 transmission and disease progression

  1996cited by this paper
• Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and Characterization

  1996cited by this paper
• Chemokines and HIV-1 second receptors. Confluence of two fields generates optimism in AIDS research.

  1996cited by this paper
• HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5

  1996cited by this paper
• Maintaining the integrity of human immunodeficiency virus sequence databases

  1996cited by this paper
• Identification of a major co-receptor for primary isolates of HIV-1

  1996influential reference
• HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 REPLICATION CAN BE INCREASED IN PERIPHERAL BLOOD OF SEROPOSITIVE PATIENTS AFTER INFLUENZA VACCINATION

  1996cited by this paper
• Rapid evolution of human immunodeficiency virus strains with increased replicative capacity during the seronegative window of primary infection

  1996cited by this paper
• Virus load in chimpanzees infected with human immunodeficiency virus type 1: effect of pre-exposure vaccination.

  1995cited by this paper
• Strategies for addressing the social and behavioral challenges of prophylactic HIV vaccine trials.

  1995cited by this paper
• Resistance of chimpanzees immunized with recombinant gp120SF2 to challenge by HIV‐1SF2

  1995cited by this paper
• Protecting HIV databases

  1995cited by this paper
• Candidate AIDS vaccines.

  1995influential reference
• High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors

  1995cited by this paper
• Maximum Discrimination Hidden Markov Models of Sequence Consensus

  1995cited by this paper
• Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120

  1995cited by this paper
• Activation of virus replication after vaccination of HIV-1-infected individuals

  1995cited by this paper
• Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer

  1995cited by this paper
• Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG

  1995cited by this paper
• Clinical, immunologic, and virologic observations related to human immunodeficiency virus (HIV) type 1 infection in a volunteer in an HIV-1 vaccine clinical trial.

  1995cited by this paper
• Clinical evaluation of Amplicor HIV-1 test for detection of human immunodeficiency virus type 1 proviral DNA in peripheral blood mononuclear cells.

  1995cited by this paper
• HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells.

  1995influential reference
• Virological analysis of primary HIV-1 infection with rapid CD4 depletion.

  1995cited by this paper
• Virologic and immunologic characterization of symptomatic and asymptomatic primary HIV-1 infection.

  1995cited by this paper
• Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1

  1995cited by this paper
• Scientific and public health rationale for HIV vaccine efficacy trials. World Health Organization.

  1995cited by this paper
• Enhancement of feline immunodeficiency virus infection after immunization with envelope glycoprotein subunit vaccines

  1995cited by this paper
• Differential Role of V3-Specific Antibodies in Neutralization Assays Involving Primary and Laboratory-Adapted Isolates of HIV Type 1

  1995influential reference
• Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines.

  1995cited by this paper
• Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection.

  1995influential reference
• The biological phenotype of HIV-1 is usually retained during and after sexual transmission.

  1994cited by this paper
• High-Titer Immune Responses Elicited by Recombinant Vaccinia Virus Priming and Particle Boosting Are Ineffective in Preventing Virulent SIV Infection

  1994cited by this paper
• Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies

  1994cited by this paper
• Human immunodeficiency virus type 1 variants with increased replicative capacity develop during the asymptomatic stage before disease progression

  1994cited by this paper
• Dilemma of Neutralization Resistance of HIV-1 Field Isolates and Vaccine Development

  1994influential reference
• fastDNAmL: a tool for construction of phylogenetic trees of DNA sequences using maximum likelihood

  1994cited by this paper
• Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS

  1994cited by this paper
• Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1

  1994influential reference
• Vaccine-induced antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins. NIAID AIDS Vaccine Clinical Trials Network.

  1994cited by this paper
• Ethical, behavioral, and social aspects of HIV vaccine trials in developing countries.

  1994cited by this paper
• The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course?

  1994cited by this paper
• HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees.

  1994cited by this paper
• Enhancement of EIAV replication and disease by immunization with a baculovirus-expressed recombinant envelope surface glycoprotein.

  1994cited by this paper
• Neutralizing Antibodies to HIV-1 in Seronegative Volunteers Immunized With Recombinant gp 120 From the MN Strain of HIV-1

  1994cited by this paper
• Mutational trends in V3 loop protein sequences observed in different genetic lineages of human immunodeficiency virus type 1

  1994cited by this paper
• The WHO and why of HIV vaccine trials

  1994cited by this paper
• AIDS vaccines. Are we ready for human efficacy trials

  1994cited by this paper
• Genetic differences between blood- and brain-derived viral sequences from human immunodeficiency virus type 1-infected patients: evidence of conserved elements in the V3 region of the envelope protein of brain-derived sequences

  1994cited by this paper
• HIV-1MN recombinant gp120 vaccine serum, which fails to neutralize primary isolates of HIV-1, does not antagonize neutralization by antibodies from infected individuals.

  1994cited by this paper
• HIV Vaccine Development: A Progress Report

  1994cited by this paper
• Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody.

  1994cited by this paper
• Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers.

  1994cited by this paper
• Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome

  1994cited by this paper
• Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody.

  1994cited by this paper
• Circulating HIV-1-infected cell burden from seroconversion to AIDS: importance of postseroconversion viral load on disease course.

  1994cited by this paper
• Variable course of primary simian immunodeficiency virus infection in lymph nodes: relation to disease progression

  1994cited by this paper
• Genotypic and phenotypic characterization of HIV-1 patients with primary infection.

  1993cited by this paper
• Scientific and social issues of human immunodeficiency virus vaccine development.

  1993cited by this paper
• Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans

  1993influential reference
• An Empirical Test of Bootstrapping as a Method for Assessing Confidence in Phylogenetic Analysis

  1993cited by this paper
• Quantitative analysis of the human immunodeficiency virus type 1 (HIV- 1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein- Barr virus in late disease

  1993cited by this paper
• Predictors of rapid progression to AIDS in HIV-1 seroconverters.

  1993cited by this paper
• Covariation of mutations in the V3 loop of human immunodeficiency virus type 1 envelope protein: an information theoretic analysis.

  1993cited by this paper
• Performance evaluation of amino acid substitution matrices

  1993cited by this paper
• Risk of developing AIDS after primary acute HIV-1 infection.

  1993cited by this paper
• The Reactivities of HIV-1+ Human Sera with Solid-Phase V3 Loop Peptides Can Be Poor Predictors of Their Reactivities with V3 Loops on Native gp120 Molecules

  1993cited by this paper
• Nonaffinity Purification of Recombinant gp120 for Use in AIDS Vaccine Development

  1993cited by this paper
• PHYLIP: phylogenetic inference package version 3.5c. Distributed over the Internet

  1993cited by this paper
• Human retroviruses and aids, 1992

  1992cited by this paper
• Efficacy of inactivated whole-virus and subunit vaccines in preventing infection and disease caused by equine infectious anemia virus

  1992cited by this paper
• Pattern-induced multi-sequence alignment (PIMA) algorithm employing secondary structure-dependent gap penalties for use in comparative protein modelling.

  1992cited by this paper
• Viral phenotype and immune response in primary human immunodeficiency virus type 1 infection.

  1992cited by this paper

• No citing papers are available for this paper.